Trials / Withdrawn
WithdrawnNCT02977689
Trial of IDH305 in IDH1 Mutant Grade II or III Glioma
Phase 2 Study of IDH305 in Subjects With IDH1 Mutant Grade II or III Glioma That Has Progressed After Observation or Radiation Therapy
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- NYU Langone Health · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to found out if the drug IDH305 is safe and effective in subjects with IDH1 mutant grade II or III glioma that has progressed after observation or radiation therapy.
Detailed description
IDH305 is an orally available, brain-penetrant, mutant-selective allosteric IDH1 inhibitor that blocks mutant IDH1-dependent production of 2-HG.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IDH305 | study drug used to inhibit IDH1 mutation in these tumors, resulting in anti-tumor activity. |
Timeline
- Start date
- 2018-04-01
- Primary completion
- 2020-04-01
- Completion
- 2020-04-01
- First posted
- 2016-11-30
- Last updated
- 2017-12-20
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02977689. Inclusion in this directory is not an endorsement.